Keros Therapeutics, Inc. — Director's Dealing 2021

Oct 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-10-19

Reporting Person: Knowles Julius (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-19	Common Stock	S	2029	$38.05	Disposed	431273	Indirect
2021-10-19	Common Stock	S	1323	$38.05	Disposed	291227	Indirect
2021-10-19	Common Stock	S	704	$38.49	Disposed	430569	Indirect
2021-10-19	Common Stock	S	460	$38.49	Disposed	290767	Indirect
2021-10-20	Common Stock	S	229	$37.55	Disposed	430340	Indirect
2021-10-20	Common Stock	S	148	$37.55	Disposed	290619	Indirect
2021-10-20	Common Stock	S	2242	$38.31	Disposed	428098	Indirect
2021-10-20	Common Stock	S	1463	$38.31	Disposed	289156	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.37 to $38.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7).

F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.74 inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $37.90 inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.91 to $38.55 inclusive.